Abstract
Venous thromboembolism (VTE) is a common complication of cancer. Prolonged use of low-molecular-weight heparin in cancer patients provides better VTE prophylaxis compared with vitamin K antagonists. Both therapeutic options have a similar safety profile. If patients on long-term oral anticoagulation are diagnosed with cancer, they should continue treatment with vitamin K antagonists.
MeSH terms
-
Administration, Oral
-
Anticoagulants / therapeutic use*
-
Blood Coagulation / drug effects
-
Heparin, Low-Molecular-Weight / therapeutic use
-
Humans
-
Neoplasms / complications*
-
Thromboembolism / drug therapy*
-
Thromboembolism / etiology
-
Venous Thrombosis / drug therapy*
-
Venous Thrombosis / etiology
-
Vitamin K / administration & dosage
-
Vitamin K / antagonists & inhibitors*
Substances
-
Anticoagulants
-
Heparin, Low-Molecular-Weight
-
Vitamin K